NASDAQ
GRTS

Gritstone Oncology Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Gritstone Oncology Inc Stock Price

Vitals

Today's Low:
$1.7
Today's High:
$1.7799
Open Price:
$1.7
52W Low:
$1.55
52W High:
$4.23
Prev. Close:
$1.7
Volume:
357462

Company Statistics

Market Cap.:
$170.33 million
Book Value:
1.201
Revenue TTM:
$11.68 million
Operating Margin TTM:
-1133.06%
Gross Profit TTM:
$-91458000
Profit Margin:
0%
Return on Assets TTM:
-37.89%
Return on Equity TTM:
-95.62%

Company Profile

Gritstone Oncology Inc had its IPO on 2018-09-28 under the ticker symbol GRTS.

The company operates in the Healthcare sector and Biotechnology industry. Gritstone Oncology Inc has a staff strength of 233 employees.

Stock update

Shares of Gritstone Oncology Inc opened at $1.7 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.7 - $1.78, and closed at $1.75.

This is a +2.94% increase from the previous day's closing price.

A total volume of 357,462 shares were traded at the close of the day’s session.

In the last one week, shares of Gritstone Oncology Inc have slipped by -4.37%.

Gritstone Oncology Inc's Key Ratios

Gritstone Oncology Inc has a market cap of $170.33 million, indicating a price to book ratio of 1.59 and a price to sales ratio of 15.92.

In the last 12-months Gritstone Oncology Inc’s revenue was $11.68 million with a gross profit of $-91458000 and an EBITDA of $-125169000. The EBITDA ratio measures Gritstone Oncology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Gritstone Oncology Inc’s operating margin was -1133.06% while its return on assets stood at -37.89% with a return of equity of -95.62%.

In Q2, Gritstone Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 64.3%.

Gritstone Oncology Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gritstone Oncology Inc’s profitability.

Gritstone Oncology Inc stock is trading at a EV to sales ratio of 12.357 and a EV to EBITDA ratio of -1.0783. Its price to sales ratio in the trailing 12-months stood at 15.92.

Gritstone Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$222.62 million
Total Liabilities
$22.11 million
Operating Cash Flow
$24.59 million
Capital Expenditure
$1.72 million
Dividend Payout Ratio
0%

Gritstone Oncology Inc ended 2024 with $222.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $222.62 million while shareholder equity stood at $109.57 million.

Gritstone Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $22.11 million in other current liabilities, 22000.00 in common stock, $-590309000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $41.41 million and cash and short-term investments were $114.53 million. The company’s total short-term debt was $4,838,000 while long-term debt stood at $29.72 million.

Gritstone Oncology Inc’s total current assets stands at $122.38 million while long-term investments were $0.00 and short-term investments were $73.12 million. Its net receivables were $399000.00 compared to accounts payable of $4.93 million and inventory worth $6.73 million.

In 2024, Gritstone Oncology Inc's operating cash flow was $24.59 million while its capital expenditure stood at $1.72 million.

Comparatively, Gritstone Oncology Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.75
52-Week High
$4.23
52-Week Low
$1.55
Analyst Target Price
$8.6

Gritstone Oncology Inc stock is currently trading at $1.75 per share. It touched a 52-week high of $4.23 and a 52-week low of $4.23. Analysts tracking the stock have a 12-month average target price of $8.6.

Its 50-day moving average was $1.87 and 200-day moving average was $2.48 The short ratio stood at 17.63 indicating a short percent outstanding of 0%.

Around 265.8% of the company’s stock are held by insiders while 5519.6% are held by institutions.

Frequently Asked Questions About Gritstone Oncology Inc

The stock symbol (also called stock or share ticker) of Gritstone Oncology Inc is GRTS

The IPO of Gritstone Oncology Inc took place on 2018-09-28

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$84.2
-4.11
-4.65%
$11.81
0.75
+6.78%
$1012
-21.35
-2.07%
$7.75
0.17
+2.24%
$8.08
-0.28
-3.35%
$1.73
-0.2
-10.36%
$56.32
-0.94
-1.64%
$0.84
-0
-0.12%
$416.27
-0.42
-0.1%
$4.08
0.03
+0.74%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Address

5959 Horton Street, EmeryVille, CA, United States, 94608